

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**LISTING OF CLAIMS:**

1. (Currently amended) A method for treating a respiratory disease in a patient while reducing or avoiding systemic side effects associated with inhaled or intranasal corticosteroids in said patient, which patient is a child and the method comprises administering to the patient a dose of a composition containing ciclesonide as the sole active ingredient, or a pharmaceutically acceptable salt thereof, wherein the dose of the composition comprises ciclesonide in an amount of from 20 to 200 µg, and wherein ciclesonide consists essentially of its R-epimer.
2. (Previously presented) The method according to claim 1, wherein the dose comprises 20, 40, 60, 80, 100, 120, 140, 160, 180 or 200 µg of ciclesonide.
3. (Previously presented) The method according to claim 1, wherein the dose comprises 40, 80 or 160 µg of ciclesonide.
4. (Previously presented) The method according to claim 1, wherein the child is a pre-pubertal human.

5. (Previously presented) The method according to claim 1, wherein the child is a human from 6 to 12 years of age.
6. (Previously presented) The method according to claim 1, wherein the dose is a daily dose in a continuous treatment regimen.
7. (Previously presented) The method according to claim 6, wherein the treatment period is more than one day.
8. (Previously presented) The method according to claim 7, wherein the treatment period is more than one week.
9. (Previously presented) The method according to claim 1, which has no effect on growth rate of the patient.
10. (Previously presented) The method according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier and/or one or more excipients.
11. (Canceled)

12. (Previously presented) The method according to claim 1, comprising a once daily dosage regimen.
13. (Previously presented) The method according to claim 1, wherein the composition is suitable for administration by inhalation.
14. (Previously presented) The method according to claim 13 wherein the composition is a pharmaceutical aerosol formulation comprising a therapeutically effective amount of ciclesonide and a hydrofluorocarbon propellant and cosolvent in an amount effective to solubilize ciclesonide and optionally a surfactant.
15. (Previously presented) The method according to claim 14, wherein the cosolvent is ethanol.
16. (Previously presented) The method according to claim 13 wherein the composition is a pharmaceutical aerosol formulation comprising particles of ciclesonide in a therapeutically effective amount and a hydrofluorocarbon propellant and 0.01 to 5 % w/w based upon propellant of polar cosolvent and optionally a surfactant.

17. (Previously presented) The method according to claim 13 wherein the composition is a dry powder and the carrier is a saccharide.
18. (Previously presented) The method according to claim 13 wherein the carrier is lactose monohydrate.
19. (Previously presented) The method according to claim 1, wherein the respiratory disease is selected from the group consisting of asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD), chronic bronchitis, wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, rhinitis, and allergic and seasonal rhinitis.
20. (Previously presented) The method according to claim 1, wherein the respiratory disease is mild or moderate asthma.
21. – 42. (Canceled)
43. (Previously presented) The method according to claim 14 wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

44. (Previously presented) The method according to claim 16 wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.
45. (Previously presented) The method according to claim 1, wherein the composition is an intranasal spray or nasal drops.
46. (Previously presented) The method according to claim 45, wherein the composition is an aqueous formulation for application to mucosa.
47. (New) The method according to claim 1, wherein the systemic side effect associated with inhaled or intranasal corticosteroids is growth suppression after long term exposure.